Offre : Twelve months post-doctoral position from September 2022

Team : Neurodegenerative Diseases

The management and treatment of Alzheimer's disease patients call for a strong diagnosis as early as possible. This project concerns the development of nuclear imaging tools to detect the early abnormal forms of Tau in the human brain with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) in order to improve the diagnosis and the follow-up of AD hallmarks. Our strategy is to develop radiolabeled nanobodies (Nbs) directed against the oligomeric form of pathologic Tau protein. We produced a Nb with both good affinity and specificity for human tau protein oligomers. We manage to increase the passage of the blood-brain barrier from this Nb, as demonstrated in vitro in an artificial model by associating it with peptides facilitating the BBB crossing. The purpose of this project is to validate in vitro and in vivo these new ligands of early pathological forms of Tau after radiolabeling with Technetium-99m (^99mTc) as well as with Gallium-68 (⁶⁸Ga). Their biodistribution will be assessed in wild-type mice. Radiotracers will then be validated in transgenic mice along SPECT/PET imaging studies and the ^99mTc and ⁶⁸Ga radiolabeled ligands will finally be compared to the most currently used radiotracer.
We are looking for a highly motivated candidate for a 12-months, full-time postdoctoral position. A solid background in the field of neurobiology and cerebral imaging is expected. Knowledge in the field of nuclear imaging will be appreciated. This project will include in vitro as well in vivo experimentation.

Read More

Contact

• ​Pr Catherine Ghezzi - Unité Mixte de Recherche UGA-INSERM 1039 "Radiopharmaceutiques Biocliniques" (+33)476637102; Catherine.Ghezziuniv-grenoble-alpes.fr (Catherine[dot]Ghezzi[at]univ-grenoble-alpes[dot]fr)

• Dr Pascale Perret - Unité Mixte de Recherche UGA-INSERM 1039 "Radiopharmaceutiques Biocliniques" (+33)476637102; pascale.perretinserm.fr (pascale[dot]perret[at]inserm[dot]fr)